Nevro says FDA clears sacroiliac joint fusion device, Nevro1

Nevro announced that the U.S. FDA cleared its sacroiliac joint fusion device, which will be marketed as Nevro1, without the need to include the screw. Nevro1, an integrated transfixing technology, is proven to immediately transfix the SI joint to allow the opportunity for long-term fusion. Self-contained, deployable titanium anchors transfix the sacrum and ilium to enhance axial and rotational stability of the joint. In addition, Nevro’s proprietary instrumentation allows for optimal intra-articular SI joint preparation which is critical to achieve joint fusion. Nevro1 comes with 3D-printed, bone-growth enhancing technology which helps promote bone cell growth and, as a result, fusion.